(Updated - December 22, 2022 6:04 AM EST)

Oppenheimer analyst Matthew Biegler downgraded Fate Therapeutics (NASDAQ: FATE) from Outperform ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE